aco-1 Antibody

What is Aconitase 1 and what cellular functions does it perform?

Aconitase 1 (ACO1), also known as cytoplasmic aconitate hydratase, IREB1, IREBP, or IRP1, is a soluble protein with a molecular weight of approximately 98.4 kDa and comprising 889 amino acid residues. It belongs to the Aconitase/IPM isomerase protein family and is primarily localized in the cytoplasm. ACO1 plays crucial roles in post-embryonic development and iron metabolism regulation. The protein has been identified as a conserved target across multiple species including human, mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken, making it valuable for comparative biology research .

How do I select the appropriate ACO1 antibody for my research?

When selecting an ACO1 antibody, consider the following key parameters: (1) validated reactivity with your species of interest (human, mouse, and rat are commonly validated); (2) application compatibility (Western blot, immunohistochemistry, immunofluorescence, or immunoprecipitation); (3) antibody type (monoclonal vs. polyclonal); and (4) immunogen used for antibody production. For example, product 12406-1-AP is a rabbit polyclonal antibody generated using Aconitase 1 fusion protein (Ag3083) as the immunogen, demonstrating reactivity with human, mouse, and rat samples across multiple applications .

What are the typical molecular characteristics observed when detecting ACO1?

The calculated molecular weight of human ACO1 is 98 kDa (889 amino acids), which corresponds to the observed molecular weight of approximately 98 kDa in Western blot applications. This consistency between the calculated and observed molecular weight suggests minimal post-translational modifications affecting the protein mass . Gene information includes GenBank Accession Number BC018103, NCBI Gene ID 48, and UNIPROT ID P21399, which can be useful for sequence verification and validation studies .

What are the optimal dilution ratios for different ACO1 antibody applications?

Based on extensive validation data, the following application-specific dilutions are recommended:

These values should be considered starting points; optimal dilutions may vary depending on specific experimental conditions and should be determined empirically for each research system .

What antigen retrieval methods are optimal for ACO1 immunohistochemistry?

For optimal antigen retrieval in immunohistochemistry applications with ACO1 antibodies, Tris-EDTA (TE) buffer at pH 9.0 is the primary recommended method. Alternatively, citrate buffer at pH 6.0 can be used if TE buffer yields suboptimal results. For paraffin-embedded tissues specifically, heat-induced epitope retrieval (HIER) at pH 6.0 has demonstrated effective results. These antigen retrieval approaches have been validated with human stomach tissue and other tissue types, ensuring consistent and specific ACO1 detection .

How should ACO1 antibodies be stored to maintain optimal activity?

For maximum stability and activity, ACO1 antibodies should be stored at -20°C, where they typically remain stable for one year after shipment. The antibodies are generally supplied in PBS buffer containing 0.02% sodium azide and 50% glycerol at pH 7.3. Notably, aliquoting is not necessary for -20°C storage of most ACO1 antibody preparations. Some smaller volume preparations (20 μL) may contain 0.1% BSA as a stabilizing agent. For repeated applications, avoid multiple freeze-thaw cycles by preparing appropriate working dilutions shortly before use .

What are the most common causes of non-specific binding when using ACO1 antibodies?

Non-specific binding when using ACO1 antibodies can result from several factors: (1) Insufficient blocking - optimize blocking conditions using 5% non-fat milk or BSA; (2) Cross-reactivity with related proteins - consider using ACO1 knockout/knockdown controls to verify specificity; (3) Excessive antibody concentration - titrate your antibody concentration systematically; (4) Improper antigen retrieval for IHC/IF applications - compare TE buffer pH 9.0 versus citrate buffer pH 6.0; and (5) Sample degradation - ensure proper sample collection and preservation. Published research has validated 12406-1-AP antibody specificity through knockout experiments, providing strong evidence for antibody specificity when used under recommended conditions .

How can I verify the specificity of ACO1 antibody detection in my experimental system?

To verify antibody specificity, implement these validation strategies: (1) Perform ACO1 gene knockdown/knockout experiments - several publications have employed this method with commercially available antibodies; (2) Compare staining patterns across multiple antibodies targeting different ACO1 epitopes; (3) Analyze tissue expression patterns - confirm detection in tissues known to express ACO1 (especially liver tissues, where strong expression is expected); (4) Use appropriate negative controls in each experiment; and (5) Compare your detection pattern with published RNA-seq data for ACO1 expression across tissues. Validation studies with NBP1-87677 antibody have shown corresponding patterns between protein detection and RNA-seq data in human kidney and skeletal muscle tissues .

What factors can affect the reproducibility of ACO1 detection across different experimental batches?

Several key factors can impact reproducibility: (1) Antibody lot-to-lot variations - record lot numbers and validate new lots against previous results; (2) Inconsistent sample preparation methods - standardize tissue processing, protein extraction, and cell lysis protocols; (3) Variability in blocking conditions or incubation times; (4) Inconsistent antigen retrieval methods for IHC applications; and (5) Differences in detection systems or imaging parameters. To minimize these variables, maintain detailed protocols, include consistent positive controls, and implement standardized quantification methods for all experiments .

How can ACO1 antibodies be utilized in studies examining the relationship between iron metabolism and oxidative stress?

ACO1 antibodies provide valuable tools for investigating iron metabolism and oxidative stress relationships through several advanced approaches: (1) Monitor ACO1's dual functionality as an enzyme/iron regulatory protein through differential detection under varying iron conditions; (2) Employ co-immunoprecipitation with ACO1 antibodies to identify interaction partners in iron-responsive element (IRE) binding during stress conditions; (3) Combine ACO1 immunofluorescence with oxidative stress markers to visualize subcellular relocalization during redox perturbations; (4) Utilize quantitative Western blotting to measure ACO1 protein levels in response to manipulations of cellular iron status; and (5) Analyze ACO1 post-translational modifications under oxidative stress conditions. Research studies have documented ACO1 protein level changes in response to high-fat diet, demonstrating its utility in metabolic research .

What are the methodological considerations when using ACO1 antibodies in multiplex immunofluorescence studies?

Implementing multiplex immunofluorescence with ACO1 antibodies requires careful consideration of: (1) Antibody species compatibility - select primary antibodies raised in different host species to avoid cross-reactivity; (2) Fluorophore selection - choose fluorophores with minimal spectral overlap and appropriate for ACO1 expression levels; (3) Sequential staining approaches - determine optimal staining order when using multiple antibodies, considering epitope masking effects; (4) Appropriate fixation methods - PFA/Triton X-100 fixation has been validated for ACO1 detection; and (5) Careful titration of each antibody individually before multiplexing. For mouse liver tissue specifically, ACO1 antibody has been successfully employed in immunofluorescence applications at dilutions ranging from 1:50 to 1:500 .

How can ACO1 antibodies contribute to understanding mitochondrial dysfunction in metabolic disorders?

ACO1 antibodies enable several sophisticated research approaches for investigating mitochondrial dysfunction: (1) Differential analysis of cytosolic ACO1 versus mitochondrial ACO2 expression to assess compartment-specific metabolic adaptations; (2) Co-localization studies with mitochondrial markers to examine potential stress-induced relocalization; (3) Comparison of ACO1 protein levels versus enzymatic activity in metabolic disease models; (4) Analysis of ACO1's iron-regulatory function in relation to mitochondrial iron homeostasis; and (5) Examination of ACO1 expression patterns in tissue-specific metabolic disease models. Western blot analysis using anti-ACO1 antibodies has successfully demonstrated changes in IRP1 (ACO1) protein levels in metabolic studies, with β-actin serving as an effective loading control .

How should researchers interpret discrepancies between ACO1 protein levels and mRNA expression?

When encountering discrepancies between ACO1 protein and mRNA levels, consider these analytical approaches: (1) Examine post-transcriptional regulation through iron regulatory element (IRE) binding activity; (2) Assess protein stability and turnover rates through cycloheximide chase experiments combined with ACO1 antibody detection; (3) Investigate microRNA-mediated regulation that may affect translation efficiency; (4) Compare nuclear versus cytoplasmic mRNA localization patterns with protein distribution; and (5) Analyze tissue-specific translational control mechanisms. Research using NBP1-87677 antibody has demonstrated correlation between protein detection and corresponding RNA-seq data in certain tissues, though discrepancies in other tissues may reflect post-transcriptional regulatory mechanisms .

What are the current methodological limitations when studying ACO1 modifications and their functional consequences?

Current methodological challenges include: (1) Limited availability of modification-specific antibodies for phosphorylation, acetylation, or ubiquitination states of ACO1; (2) Difficulties in preserving labile iron-sulfur cluster integrity during sample preparation; (3) Challenges in distinguishing the aconitase enzymatic form from the iron regulatory protein form using standard antibodies; (4) Technical hurdles in simultaneously visualizing ACO1 binding to IRE-containing mRNAs while detecting the protein; and (5) Limitations in temporal resolution when tracking rapid changes in ACO1 functional states. Researchers should consider complementing antibody-based detection with activity assays, mass spectrometry approaches, and genetic models expressing tagged ACO1 variants to overcome these limitations .

How can researchers effectively combine ACO1 antibody-based techniques with functional metabolic assays?

To integrate ACO1 antibody methods with functional metabolic analysis: (1) Pair Western blot quantification of ACO1 with enzymatic activity assays to correlate protein levels with functional capacity; (2) Combine immunofluorescence localization studies with metabolite profiling in the same experimental model; (3) Design sequential immunoprecipitation and metabolomic analysis protocols to link ACO1 interaction partners with specific metabolic signatures; (4) Utilize flow cytometry with ACO1 antibodies alongside metabolic dyes to correlate single-cell protein expression with metabolic state; and (5) Implement tissue clearing techniques with ACO1 immunostaining to visualize three-dimensional distribution in relation to metabolic gradients in intact tissues. This multidisciplinary approach provides more comprehensive insights than either technique alone .

How might advanced imaging techniques enhance the utility of ACO1 antibodies in research?

Emerging imaging approaches offer new possibilities for ACO1 research: (1) Super-resolution microscopy can reveal previously undetectable subcellular distribution patterns of ACO1, particularly in relation to stress granules and processing bodies; (2) Live-cell imaging with genetically encoded tags calibrated against antibody detection can track dynamic ACO1 relocalization during stress responses; (3) Correlative light and electron microscopy (CLEM) using ACO1 antibodies can bridge ultrastructural observations with functional data; (4) Tissue clearing techniques combined with whole-organ imaging can map ACO1 distribution across complex tissue architectures; and (5) Expansion microscopy may reveal nanoscale organization of ACO1 in relation to translational machinery components. Current antibodies already demonstrate excellent performance in multiple imaging applications, providing a foundation for these advanced techniques .

What are the theoretical implications of studying ACO1 post-translational modifications using current antibody resources?

The study of ACO1 post-translational modifications presents intriguing research directions: (1) Development of modification-specific antibodies could reveal how oxidative stress triggers conversion between enzymatic and RNA-binding functions; (2) Analysis of iron-dependent structural changes might identify potential therapeutic intervention points in disorders of iron metabolism; (3) Investigation of tissue-specific modification patterns could explain differential ACO1 activity across organs; (4) Examination of how modifications affect ACO1's interaction with the iron-sulfur cluster assembly machinery; and (5) Exploration of potential crosstalk between ACO1 modifications and mitochondrial function. Current general ACO1 antibodies provide valuable tools for immunoprecipitation of modified forms for subsequent mass spectrometry analysis .